Clinical benefit of crenolanib, with or without salvage chemotherapy, in multiply relapsed, FLT3 mutant AML patients after prior treatment with gilteritinib Meeting Abstract
| Authors: | Goldberg, A. D.; Geyer, M. B.; Kell, J.; Di Bona, E.; Pardee, T. S.; Bhave, R.; Grunwald, M. R.; Marconi, G.; Wang, Y. J.; Pathan, A.; Messahel, B. |
| Abstract Title: | Clinical benefit of crenolanib, with or without salvage chemotherapy, in multiply relapsed, FLT3 mutant AML patients after prior treatment with gilteritinib |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205603264 |
| DOI: | 10.1182/blood-2020-139898 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 8 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
